ALN-6400 Clinical Trials (2026): 2 Studies for Heavy Menstrual Bleeding (HMB) & Hereditary Hemorrhagic Telangiectasia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 ALN-6400 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Heavy Menstrual Bleeding (HMB) & Hereditary Hemorrhagic Telangiectasia) and 144 total planned enrollment. 2 ALN-6400 clinical trials are actively recruiting at 8 U.S. sites across 8 states. Most recent activity: NCT07575308 (Nov 2028).
Where to Participate: All ALN-6400 Trial Sites in the U.S. (8 sites across 8 states)
Every actively recruiting ALN-6400trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Clinical Trial Site | Birmingham35233 | NCT06659640 | Map |
| CA | Clinical Trial Site | Cypress90630 | NCT06659640 | Map |
| FL | Clinical Trial Site | Gainesville32608 | NCT06659640 | Map |
| IN | Clinical Trial Site | Indianapolis46260 | NCT06659640 | Map |
| MA | Clinical Trial Site | Boston02114 | NCT06659640 | Map |
| MN | Clinical Trial Site | Rochester55905 | NCT06659640 | Map |
| MO | Clinical Trial Site | St Louis63110 | NCT06659640 | Map |
| NC | Clinical Trial Site | Chapel Hill27514 | NCT06659640 | Map |
ALN-6400 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | not yet recruiting | Total |
|---|---|---|---|
| P1/P2 | 1 | 1 | |
| P2 | 1 | 1 |
Recruiting ALN-6400 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07575308 | HMBeaconHMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB | P2 | Von Willebrand Disease (VWD) | 24 | May 2026 |
| NCT06659640 | InsigHHTA Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | P1/P2 | Hereditary Hemorrhagic Telangiectasia | 120 | Nov 2024 |
ALN-6400 clinical trials by indication
Von Willebrand Disease (VWD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07575308 | HMBeacon | P2 | not yet recruiting | HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB |
Hereditary Hemorrhagic Telangiectasia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06659640 | InsigHHT | P1/P2 | recruiting | A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) |
ALN-6400 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| HMBeacon | NCT07575308 | P2 | not yet recruiting | Von Willebrand Disease (VWD) | 24 | — |
All ALN-6400 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07575308 | HMBeacon | HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB | P2 | not yet recruiting | 24 | Alnylam Pharmaceuticals | May 2026 |
| NCT06659640 | InsigHHT | A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | P1/P2 | recruiting | 120 | Alnylam Pharmaceuticals | Nov 2024 |
ALN-6400 clinical trials: frequently asked questions
- How many ALN-6400 clinical trials are there?
- 2 ALN-6400 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are ALN-6400 clinical trials recruiting in 2026?
- Yes — 1 ALN-6400 trial is actively recruiting in 2026, with 8 U.S. sites across 8 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is ALN-6400 being studied for?
- ALN-6400 is being studied for Heavy Menstrual Bleeding (HMB), Hereditary Hemorrhagic Telangiectasia, Von Willebrand Disease (VWD). The trials are grouped by indication on this page.
- What phase is ALN-6400 in?
- ALN-6400 clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors ALN-6400 clinical trials?
- The lead sponsor across the most ALN-6400 trials is Alnylam Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ALN-6400as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: